Peptide deformylase inhibitors

1. A compound according to formula (I):

wherein:

R is selected from the group consisting of:

C 2-6 alkyl (optionally substituted by alkoxy, halogen, or C 1-3 alkylsulfanyl);

C 2-6 alkenyl (optionally substituted by alkoxy, halogen, or C 1-3 alkylsulfanyl);

C 2-6 alkynyl (optionally substituted by alkoxy, halogen, or C 1-3 alkylsulfanyl);

(CH 2 ) n —C 3-6 carbocycle (optionally substituted by alkoxy, halogen, or C 1-3 alkylsulfanyl); and (CH 2 ) n —R4, wherein R4 is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane and benzo[1,3]dioxole; R4 is optionally substituted by one or more substituents selected from Cl, Br, I, C 1-3 alkyl (optionally substituted by one to three F) and C 1-2 alkoxy (optionally substituted by one to three F);

R1 represents hydrogen or C 1-4 alkyl;

R2 represents C 1-6 alkyl, ArC 1-4 alkyl, wherein substitution is through the alkyl carbon, or Ar;

Ar is selected from the group consisting of phenyl, naphthyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, and pyrimidyl; all of which may be unsubstituted or substituted by one or more Z 1 or Z 2 groups;

Z 1 and Z 2 are, independently, selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 alkoxy, (CH 2 ) n CO 2 R1, C(O)NRR1, CN, (CH 2 ) n OH, NO 2 , halogen, NHR 2 , and NHC(O)R2; and

n is an integer from 0 to 4; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 selected from the group consisting of:

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}benzenesulfonamide;

4-Chloro-N-{2-[(formylhydroxyamino)methyl]heptanoyl}benzenesulfonamide;

4-tert-Butyl-N-{2-[(formylhydroxyamino)methyl]heptanoyl}benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}methanesulfonamide;

Butane-1-sulfonic acid {2[(formylhydroxyamino)methyl]heptanoyl}amide;

Propane-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-heptanoyl}amide;

4-{2-[(Formylhydroxyamino)methyl]heptanoylsulfamoyl}benzoic acid methyl ester;

4-Chloro-N-{2-[(formylhydroxyamino)methyl]-3-phenyl-propanoyl}benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]-3-phenyl-propanoyl}benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid {2-[(formylhydroxyamino)methyl]heptanoyl}amide;

N-{2-[(Formylhydroxyamino)methyl]-4-phenyl-butanoyl}benzenesulfonamide;

Butane-1-sulfonic acid {2-[(formylhydroxyamino)methyl]-4-phenyl-butanoyl}amide;

Propane-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-3-phenyl-propanoyl}amide;

Biphenyl-4-sulfonic acid {2-[(formyl-hydroxy-amino)-methyl]-heptanoyl}amide;

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]heptanoyl}amide;

4-{2-[(Formylhydroxyamino)methyl]heptanoylsulfamoyl}benzoic acid propyl ester;

Naphthalene-1-sulfonic acid {2-[(formylhydroxyamino)methyl]heptanoyl}amide;

N-{2-[(Formylhydroxyamino)methyl]-5-methylhexanoyl}benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid {2-[(formylhydroxyamino)methyl]-5-methyl-hexanoyl}amide;

4-Dimethylamino-N-{2-[(formylhydroxyamino)methyl]-5-methyl-hexanoyl}benzenesulfonamide;

N-[2-(2,6-Dichloro-benzyl)-3-(formylhydroxyamino)propanoyl]benzenesulfonamide;

Dimethylamino-N-{2-[(formylhydroxyamino)methyl]heptanoyl}benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid [2-(2,6-dichlorobenzyl)-3-(formylhydroxyamino)propanoyl]amide;

5-Dimethylamino-naphthalene-1-sulfonic acid [2-(2,6-dichlorobenzyl)-3-(formylhydroxyamino)propanoyl]amide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-methyl-benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-phenoxy-benzenesulfonamide;

N-{2-[(Formylhydroxyamino)methyl]heptanoyl}-4-methoxy-benzenesulfonamide;

5-Methyl-pyridine-2-sulfonic acid {3-(3,4-dichlorophenyl)-2-[(formylhydroxyamino)methyl]propanoyl}amide;

N-{2-[(Formylhydroxyamino)methyl]hexanoyl}benzenesulfonamide;

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]hexanoyl}amide;

N-{2-[(Formylhydroxyamino)methyl]hexanoyl}-4-phenoxy-benzenesulfonamide;

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]-3-methyl-butanoyl}amide;

5-Dimethylamino-naphthalene-1-sulfonic acid {(R)-2-[(formylhydroxyamino)methyl]heptanoyl}amide;

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]pentanoyl}amide;

Biphenyl-4-sulfonic acid {2-[(formylhydroxyamino)methyl]pentanoyl}amide;

Biphenyl-4-sulfonic acid {2-[(formylhydroxyamino)-methyl]-4-methyl-pentanoyl}amide; and

5-Dimethylamino-naphthalene-1-sulfonic acid {2-[(formylhydroxyamino) methyl]-4-methyl-pentanoyl}amide; or a pharmaceutically acceptable salt thereof.

3. A method of treating a bacterial infection by administering to a subject in need of treatment a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.